Strauss J M, Giest J
Klinik für Anästhesiologie und Operative Intensivmedizin, HELIOS Klinikum Berlin, Germany.
Anaesthesist. 2003 Sep;52(9):763-77. doi: 10.1007/s00101-003-0560-5.
Since venous cannulation in children has become easier and extensive experience has been gained with total intravenous anaesthesia (TIVA) in adults, the interest in TIVA for children has recently increased. An intensified sensitivity of the operating room atmosphere to contamination with volatile anaesthetic agents is another important reason to choose intravenous techniques for paediatric anaesthesia. One of the most interesting agents for TIVA in paediatric anaesthesia is propofol. The pharmacokinetic and pharmacodynamic data for modern intravenous drugs is poor. Because the interpatient variability is relatively large, pharmacokinetic data can only provide guidelines for the dosage of propofol. Propofol has a rapid and smooth onset of action and is as easy to titrate in children as in adults. Propofol can be excellently controlled. Severe haemodynamic side-effects are missing in healthy children and plasma is cleared rapidly of propofol by redistribution and metabolism. There is no evidence of significant accumulation, not even after prolonged infusion times. Because propofol has no analgetic properties it must be combined with analgetics or a regional block for all painful procedures. The combination with the ultra-short acting remifentanil is a major advantage, but requires effective analgetic concepts for painful procedures. In comparison the combination of propofol with long acting opioids abolishes some of the favourable properties of propofol. Further studies of the kinetics and dynamics of propofol and other intravenous agents are needed in paediatrics which should focus on age, maturity and severity of illness. The whole importance of the propofol-infusion syndrome has to be cleared up urgently. TIVA has an important significance in paediatric anaesthesia for diagnostic and therapeutic procedures, especially where these have to be repeated. In day-case anaesthesia TIVA has advantages for all short procedures and for ENT and ophthalmic surgery: even after prolonged infusion children have an short recovery time. There is no evidence of agitation or other behavioural disorders after TIVA with propofol in paediatric anaesthesia. Propofol has anti-emetic properties. TIVA with propofol can be combined with regional anaesthesia advantageously to provide long-lasting analgesia after surgery. TIVA with propofol has been used successfully for sedation of spontaneously breathing children for MRI and CT and other procedures with open airways like bronchoscopy or endoscopy. Propofol facilitates endotracheal intubation without the use of muscle relaxants. Of course, in malignant hyperthermia TIVA will continue to be the technique of choice. Nothing is known about awareness under TIVA in paediatric patients. TIVA must be considered by comparison with the volatile agents. The use of ultra-short acting agents may cause problems such as awareness, vagal response, involuntary movements and in some cases slow recovery after prolonged infusion of propofol. But it is not known exactly how often this happens during paediatric anaesthesia. With TIVA an effective postoperative analgesia must be provided. Newer administration techniques such as the target-controlled infusions or closed-loop control systems are under development and will help to minimise the potential risk of overdosage with TIVA in paediatrics. At the present TIVA is an interesting and practicable alternative to volatile anaesthesia for pre-school and school children. TIVA with propofol in infants younger than 1 year old requires extensive experience with TIVA in older children and with the handling of this special age group and should be undertaken with maximum precautionary measures.
由于儿童静脉置管变得更加容易,并且成人全静脉麻醉(TIVA)已积累了丰富经验,近年来对儿童TIVA的兴趣有所增加。手术室环境对挥发性麻醉剂污染的敏感性增强是选择静脉麻醉技术用于小儿麻醉的另一个重要原因。丙泊酚是小儿麻醉中TIVA最具吸引力的药物之一。现代静脉药物的药代动力学和药效学数据不完善。由于患者间变异性相对较大,药代动力学数据只能为丙泊酚的剂量提供指导。丙泊酚起效迅速且平稳,在儿童中滴定与成人一样容易。丙泊酚可以得到很好的控制。健康儿童不会出现严重的血流动力学副作用,丙泊酚通过再分布和代谢在血浆中迅速清除。没有证据表明会有明显蓄积,即使长时间输注后也是如此。由于丙泊酚没有镇痛特性,在所有疼痛操作中必须与镇痛药或区域阻滞联合使用。与超短效瑞芬太尼联合是一个主要优势,但疼痛操作需要有效的镇痛方案。相比之下,丙泊酚与长效阿片类药物联合使用会消除丙泊酚的一些有利特性。儿科需要进一步研究丙泊酚和其他静脉药物的动力学和动态学,研究应聚焦于年龄、成熟度和疾病严重程度。必须紧急弄清楚丙泊酚输注综合征的整体重要性。TIVA在儿科麻醉的诊断和治疗操作中具有重要意义,尤其是那些需要重复进行的操作。在日间手术麻醉中,TIVA对所有短时间手术以及耳鼻喉科和眼科手术具有优势:即使长时间输注后,儿童恢复时间也很短。小儿麻醉中使用丙泊酚进行TIVA后,没有躁动或其他行为障碍的证据。丙泊酚具有抗呕吐特性。丙泊酚TIVA可与区域麻醉有利地联合使用,以提供术后长效镇痛。丙泊酚TIVA已成功用于自主呼吸儿童的MRI和CT镇静以及支气管镜检查或内镜检查等其他气道开放操作的镇静。丙泊酚无需使用肌肉松弛剂即可促进气管插管。当然,在恶性高热情况下,TIVA仍将是首选技术。对于小儿患者TIVA下的知晓情况尚不清楚。必须将TIVA与挥发性麻醉剂进行比较考虑。使用超短效药物可能会导致一些问题,如知晓、迷走反应、不自主运动,在某些情况下,长时间输注丙泊酚后恢复缓慢。但不清楚在小儿麻醉期间这种情况发生的频率。采用TIVA必须提供有效的术后镇痛。诸如靶控输注或闭环控制系统等更新的给药技术正在研发中,将有助于将小儿TIVA用药过量的潜在风险降至最低。目前,对于学龄前和学龄儿童,TIVA是挥发性麻醉的一种有趣且可行的替代方法。对于1岁以下婴儿使用丙泊酚进行TIVA需要在大龄儿童TIVA及处理这个特殊年龄组方面有丰富经验,并且应采取最大的预防措施。